CRB Horizons Report - Life Sciences 2021
Our Horizons: Life Sciences report, built on the inputs of more than 500 industry leaders, explores the evolving science and business of drug manufacturing and the operational shifts our industry must make, especially as COVID-19 has changed our work and our world.
CRB introduces its newest Horizons report, exploring the life sciences industry in 2021 and beyond.
The COVID-19 pandemic has triggered significant changes in the life sciences industry: new ways of accelerating from R&D to manufacturing, new models for partnership and collaboration, and a whole new mindset, which casts off our industry’s conservative nature in favor of more innovation, more speed, and more flexibility in the name of more lives saved. We will one day defeat this pandemic, but the waves of change that are overtaking the life sciences are only just gathering momentum.
This survey is our opportunity to raise a periscope above those waves.
Analyzing the inputs of more than 500 industry leaders, CRB's subject matter experts explore the changing ways therapies work and the change work of making therapies.
